Results 231 to 240 of about 12,926,306 (256)
ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. [PDF]
Cell DiscovHan L +10 more
europepmc +1 more source
The toxicity profile and temporal dynamics of dual PD-1/CTLA-4 immune checkpoint blockade: a real-world pharmacovigilance study using the FAERS database. [PDF]
Front ImmunolYang Y +5 more
europepmc +1 more source
Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. [PDF]
J Immunother CancerSquifflet P +6 more
europepmc +1 more source
Investigation of the CTLA-4-CD28 Axis in Oral Squamous Cell Carcinoma. [PDF]
J Clin MedFeldmeier F +9 more
europepmc +1 more source
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Cancer Cell, 2018 (Summary) With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the ...
Andrew Georgiou +2 more
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop
Cell, 2021Shivashankar Othy +2 more
exaly